Saturday 17 October 2026
Export FLNA’s income statement to Excel — free account
Cassava Sciences, Inc.
FLNA Healthcare Biotechnology
In the quarter to June 2026, EPS grew 80.4% and free cash flow grew 21.7%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
0.71
0.05
−6.58%
Follow FLNA
Cassava Sciences, Inc. (FLNA) P/E ratio
Cassava Sciences, Inc. has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (October 2026) to 0.0× (October 2026) — the current reading is the highest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|
Against its own ten years
Low 0.0×
High 0.0×
Ten-year median
0.0×
Current reading's percentile
100
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| EDSA Edesa Biotech, Inc. compare | n/m |
| LBPS 4D pharma PLC Sponsored ADR compare | n/m |
| NNVC NanoViricides, Inc. compare | n/m |
| EXOZ eXoZymes Inc. compare | n/m |
| CRVO CervoMed Inc. compare | n/m |
| FLNA Cassava Sciences, Inc. | n/m |
| LITS Lite Strategy, Inc. compare | n/m |
| IRLA Quince Therapeutics, Inc. compare | n/m |
| LIANY LianBio Sponsored ADR compare | 0.0× |
| Biotechnology industry median | 8.5× |
| Healthcare sector median | 23.0× |
| Market median | 18.1× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)